| # | Title | Journal | Year | Citations |
|---|
| 1 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | Autophagy | 2016 | 4,701 |
| 2 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | Lancet Oncology, The | 2014 | 3,343 |
| 3 | Cancer treatment and survivorship statistics, 2019 | Ca-A Cancer Journal for Clinicians | 2019 | 3,303 |
| 4 | Cancer treatment and survivorship statistics, 2022 | Ca-A Cancer Journal for Clinicians | 2022 | 897 |
| 5 | Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial | Lancet, The | 2016 | 724 |
| 6 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis | Lancet Oncology, The | 2016 | 719 |
| 7 | Breast Cancer Statistics, 2022 | Ca-A Cancer Journal for Clinicians | 2022 | 611 |
| 8 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report | Blood | 2015 | 586 |
| 9 | Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions | PLoS ONE | 2013 | 575 |
| 10 | The genetic landscape of mutations in Burkitt lymphoma | Nature Genetics | 2012 | 517 |
| 11 | Perspectives for Cancer Prevention With Natural Compounds | Journal of Clinical Oncology | 2009 | 471 |
| 12 | Lung cancer: New biological insights and recent therapeutic advances | Ca-A Cancer Journal for Clinicians | 2011 | 413 |
| 13 | A Reexamination of Active and Passive Tumor Targeting by Using Rod-Shaped Gold Nanocrystals and Covalently Conjugated Peptide Ligands | ACS Nano | 2010 | 395 |
| 14 | Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group | Lancet Oncology, The | 2017 | 394 |
| 15 | Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma | Blood | 2017 | 391 |
| 16 | Broad targeting of angiogenesis for cancer prevention and therapy | Seminars in Cancer Biology | 2015 | 375 |
| 17 | Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology | Ca-A Cancer Journal for Clinicians | 2017 | 364 |
| 18 | Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma | Blood | 2016 | 347 |
| 19 | Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer | Breast Cancer Research and Treatment | 2017 | 335 |
| 20 | A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer | JAMA Oncology | 2020 | 293 |
| 21 | TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer | Annals of Oncology | 2020 | 289 |
| 22 | International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation | Blood | 2011 | 282 |
| 23 | Head and neck cancer | Lancet, The | 2021 | 280 |
| 24 | Prostate cancer epidemiology in the United States | World Journal of Urology | 2012 | 271 |
| 25 | Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer | Pharmacological Research | 2020 | 269 |
| 26 | Adenoid cystic carcinoma of the head and neck | Cancer | 2012 | 251 |
| 27 | Current approaches to the treatment of metastatic brain tumours | Nature Reviews Clinical Oncology | 2014 | 233 |
| 28 | Designing a broad-spectrum integrative approach for cancer prevention and treatment | Seminars in Cancer Biology | 2015 | 220 |
| 29 | International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) | Leukemia | 2009 | 207 |
| 30 | Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 | Clinical Cancer Research | 2015 | 205 |
| 31 | Review on Molecular and Therapeutic Potential of Thymoquinone in Cancer | Nutrition and Cancer | 2010 | 198 |
| 32 | Naringenin as a potential immunomodulator in therapeutics | Pharmacological Research | 2018 | 181 |
| 33 | MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology and Oncology | 2019 | 181 |
| 34 | Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell–Cancer-Associated Fibroblast Interactions during Collective Invasion | Clinical Cancer Research | 2018 | 175 |
| 35 | Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009 | Cancer | 2013 | 166 |
| 36 | Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma | Pancreas | 2013 | 166 |
| 37 | Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis | Hepatology | 2010 | 158 |
| 38 | Sustained antibody responses depend on CD28 function in bone marrow–resident plasma cells | Journal of Experimental Medicine | 2011 | 156 |
| 39 | Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma | Journal of Clinical Oncology | 2020 | 148 |
| 40 | Epigenetic programming underpins B cell dysfunction in human SLE | Nature Immunology | 2019 | 142 |
| 41 | Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer | Journal of Thoracic Oncology | 2018 | 134 |
| 42 | HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium | Cancer | 2017 | 132 |
| 43 | High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma | Blood Cancer Journal | 2017 | 132 |
| 44 | Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma | Thyroid | 2014 | 130 |
| 45 | Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors | Blood | 2011 | 125 |
| 46 | Pyroptosis at the forefront of anticancer immunity | Journal of Experimental and Clinical Cancer Research | 2021 | 124 |
| 47 | Toward optimal therapy for inhibitors in hemophilia | Blood | 2014 | 120 |
| 48 | High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action | Cytometry Part A: the Journal of the International Society for Analytical Cytology | 2019 | 117 |
| 49 | Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment | Cancer Research | 2017 | 113 |
| 50 | The whole-genome landscape of Burkitt lymphoma subtypes | Blood | 2019 | 113 |
